biostudies-literatureUnknown11(2)Liu X<h4>Background</h4>The TACTIC CRC-02 study evaluated the efficacy and safety of tislelizumab, a humanized immunoglobulin G4 monoclonal antibody targeting programmed cell death protein 1, combined with standard XELOX plus bevacizumab as first-line treatment of microsatellite stable/proficient mismatch repair (MSS/pMMR) RAS-mutant metastatic colorectal cancer (mCRC).<h4>Patients and methods</h4>TACTIC CRC-02 was a single-center, single-arm, open-label, phase II trial. Eligible patients had previously untreated, unresectable MSS/pMMR, RAS-mutant mCRC and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received intravenous tislelizumab (200 mg/m²), bevacizumab (7.5 mg/kg), and oxaliplatin (130 mg/m²) on day 1, with oral capecitabine (1000 mg/mESMO open106056https://www.ebi.ac.uk/biostudies/studies/S-EPMC12870864biostudies-literatureTislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study.PMC12870864Yang LZhang HMa XZhang LCao BLiu XZhang WYang WJiang ZOu KWang QZhou ALu JGao LfalseTislelizumab plus bevacizumab and XELOX as first-line treatment of MSS/pMMR RAS-mutant metastatic colorectal cancer (TACTIC CRC-02): a phase II study.<h4>Background</h4>The TACTIC CRC-02 study evaluated the efficacy and safety of tislelizumab, a humanized immunoglobulin G4 monoclonal antibody targeting programmed cell death protein 1, combined with standard XELOX plus bevacizumab as first-line treatment of microsatellite stable/proficient mismatch repair (MSS/pMMR) RAS-mutant metastatic colorectal cancer (mCRC).<h4>Patients and methods</h4>TACTIC CRC-02 was a single-center, single-arm, open-label, phase II trial. Eligible patients had previously untreated, unresectable MSS/pMMR, RAS-mutant mCRC and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received intravenous tislelizumab (200 mg/m²), bevacizumab (7.5 mg/kg), and oxaliplatin (130 mg/m²) on day 1, with oral capecitabine (1000 mg/m2026-01-01T00:00:00Z2026 Jan2026-07-15T06:15:35.965Z2026-06-30T03:22:07.091ZS-EPMC128708644161069110.1016/j.esmoop.2025.106056